Amphotericin B-resistant yeast infection in severely immunocompromised patients

William G. Powderly, George S. Kobayashi, Geoffrey P. Herzig, Gerald Medoff

Research output: Contribution to journalArticlepeer-review

208 Scopus citations

Abstract

Systemic yeast infections are a major cause of morbidity and mortality in severely immunocompromised patients. The in vitro susceptibility to amphotericin B of 29 yeasts causing fungemia was examined in 26 patients undergoing allogeneic or autologous bone marrow transplantation and/or myelosuppressive chemotherapy. The minimal inhibitory concentrations (MICs) of amphotericin B observed with blood isolates from these patients were significantly higher than those observed with blood, sputum, or skin isolates from non-immunocompromised patients (p <0.01). All episodes (10 of 10) of bloodstream infection in immunocompromised patients caused by isolates with MICs greater than 0.8 μg/ml were fatal, versus eight of 17 episodes of bloodstream infection caused by yeasts with MICs of 0.8 μg/ml or less (p = 0.04). Although 15 of 26 patients received empiric treatment with amphotericin B before laboratory evidence of fungemia developed, the amphotericin B susceptibilities of their isolates were not significantly different from those of patients who had not received empiric amphotericin B treatment. It is concluded that yeast fungemia in severely immunocompromised patients is often caused by organisms resistant to the usual concentrations of amphotericin B obtainable in vivo, and that this finding is clinically significant.

Original languageEnglish
Pages (from-to)826-832
Number of pages7
JournalThe American journal of medicine
Volume84
Issue number5
DOIs
StatePublished - May 1988

Fingerprint

Dive into the research topics of 'Amphotericin B-resistant yeast infection in severely immunocompromised patients'. Together they form a unique fingerprint.

Cite this